{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T21:01:47Z","timestamp":1762981307901,"version":"3.37.3"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T00:00:00Z","timestamp":1643241600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T00:00:00Z","timestamp":1643241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002001","name":"Health Services and Delivery Research Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002001","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Clin Immunol"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Terminal complement pathway deficiencies often present with severe and recurrent infections. There is a lack of good-quality data on these rare conditions. This study investigated the clinical outcome and genetic variation in a large UK multi-center cohort with primary and secondary terminal complement deficiencies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Clinicians from seven UK centers provided anonymised demographic, clinical, and laboratory data on patients with terminal complement deficiencies, which were collated and analysed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Forty patients, median age 19 (range 3\u201362) years, were identified with terminal complement deficiencies. Ten (62%) of 16 patients with low serum C5 concentrations had underlying pathogenic <jats:italic>CFH<\/jats:italic> or <jats:italic>CFI<\/jats:italic> gene variants. Two-thirds were from consanguineous Asian families, and 80% had an affected family member. The median age of the first infection was 9\u00a0years. Forty-three percent suffered meningococcal serotype B and 43% serotype Y infections. Nine (22%) were treated in intensive care for meningococcal septicaemia. Two patients had died, one from intercurrent COVID-19. Twenty-one (52%) were asymptomatic and diagnosed based on family history. All but one patient had received booster meningococcal vaccines and 70% were taking prophylactic antibiotics.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>The genetic etiology and clinical course of patients with primary and secondary terminal complement deficiency are variable. Patients with low antigenic C5 concentrations require genetic testing, as the low level may reflect consumption secondary to regulatory defects in the pathway. Screening of siblings is important. Only half of the patients develop septicaemia, but all should have a clear management plan.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10875-022-01213-9","type":"journal-article","created":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T15:24:02Z","timestamp":1643297042000},"page":"665-671","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Clinical Outcome and Underlying Genetic Cause of Functional Terminal Complement Pathway Deficiencies in a Multicenter UK Cohort"],"prefix":"10.1007","volume":"42","author":[{"given":"Annalie","family":"Shears","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cathal","family":"Steele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamie","family":"Craig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Jolles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sinisa","family":"Savic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosie","family":"Hague","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanya","family":"Coulter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Herriot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter D.","family":"Arkwright","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,27]]},"reference":[{"key":"1213_CR1","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.3389\/fimmu.2019.01936","volume":"10","author":"C El Sissy","year":"2019","unstructured":"El Sissy C, Rosain J, Vieira-Martins P, Bordereau P, Gruber A, Devriese M, et al. Clinical and genetic spectrum of a large cohort with total and Sub-total complement deficiencies. Front Immunol. 2019;10:1936.","journal-title":"Front Immunol"},{"key":"1213_CR2","doi-asserted-by":"publisher","first-page":"601405","DOI":"10.3389\/fimmu.2020.601405","volume":"11","author":"PA Krawczyk","year":"2020","unstructured":"Krawczyk PA, Laub M, Kozik P. To kill but not be killed: controlling the activity of mammalian pore-forming proteins. Front Immunol. 2020;11:601405.","journal-title":"Front Immunol"},{"key":"1213_CR3","doi-asserted-by":"crossref","unstructured":"Arkwright PD 2021 Chapter 18. Primary immunodeficiencies of complement. In: Primary and secondary immunodeficiency: a case-based guide to evaluation and management. Ed Jonathan Bernstein, Springer Nature Switzerland AG, 313\u2013330.","DOI":"10.1007\/978-3-030-57157-3_18"},{"key":"1213_CR4","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s10875-015-0137-5","volume":"35","author":"AJ Turley","year":"2015","unstructured":"Turley AJ, Gathmann B, Bangs C, Bradbury M, Seneviratne S, Gonzalez-Granado LI, Hackett S, Kutukculer N, et al. Spectrum and management of complement immunodeficiencies (excluding hereditary angioedema) across Europe. J Clin Immunol. 2015;35:199\u2013205.","journal-title":"J Clin Immunol"},{"issue":"19","key":"1213_CR5","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1186\/s12879-019-4146-5","volume":"14","author":"SN Ladhani","year":"2019","unstructured":"Ladhani SN, Campbell H, Lucidarme J, Gray S, Parikh S, Willerton L, Clark SA, Lekshmi A, et al. Invasive meningococcal disease in patients with complement deficiencies: a case series (2008\u20132017). BMC Infect Dis. 2019;14(19):522.","journal-title":"BMC Infect Dis"},{"key":"1213_CR6","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1093\/infdis\/jix143","volume":"215","author":"J Rosain","year":"2017","unstructured":"Rosain J, Hong E, Fieschi C, Martins PV, El Sissy C, Deghmane AE, et al. Strains responsible for invasive meningococcal disease in patients with terminal complement pathway deficiencies. J Infect Dis. 2017;215:1331\u20138.","journal-title":"J Infect Dis"},{"key":"1213_CR7","doi-asserted-by":"publisher","first-page":"386","DOI":"10.2500\/aap.2020.41.200039","volume":"41","author":"CK Rauscher","year":"2020","unstructured":"Rauscher CK, Fajt ML, Bryk J, Petrov AA. Clinical implications of C6 complement component deficiency. Allergy Asthma Proc. 2020;41:386\u20138.","journal-title":"Allergy Asthma Proc"},{"key":"1213_CR8","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.molimm.2014.11.010","volume":"64","author":"EP Owen","year":"2015","unstructured":"Owen EP, W\u00fcrzner R, Leisegang F, Rizkallah P, Whitelaw A, Simpson J, Thomas AD, Harris CL, et al. A complement C5 gene mutation, c.754G>A:p.A252T, is common in the Western Cape, South Africa and found to be homozygous in seven percent of Black African meningococcal disease cases. Mol Immunol. 2015;64:170\u20136.","journal-title":"Mol Immunol"},{"key":"1213_CR9","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.molimm.2014.11.010","volume":"64","author":"EP Owen","year":"2015","unstructured":"Owen EP, W\u00fcrzner R, Leisegang F, Rizkallah P, Whitelaw A, Simpson J, et al. A complement C5 gene mutation, c.754G>A:p.A252T, is common in the Western Cape, South Africa and found to be homozygous in seven percent of Black African meningococcal disease cases. Mol Immunol. 2015;64:170\u20136.","journal-title":"Mol Immunol"},{"key":"1213_CR10","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1002\/eji.200636812","volume":"37","author":"MA Rameix-Welti","year":"2007","unstructured":"Rameix-Welti MA, R\u00e9gnier CH, Bienaim\u00e9 F, Blouin J, Schifferli J, Fridman WH, Saut\u00e8s-Fridman C, et al. Hereditary complement C7 deficiency in nine families: subtotal C7 deficiency revisited. Eur J Immunol. 2007;37:1377\u201385.","journal-title":"Eur J Immunol"},{"key":"1213_CR11","doi-asserted-by":"publisher","first-page":"e3548","DOI":"10.1097\/MD.0000000000003548","volume":"95","author":"A Audemard-Verger","year":"2016","unstructured":"Audemard-Verger A, Descloux E, Ponard D, Deroux A, Fantin B, Fieschi C, et al. Infections revealing complement deficiency in adults: a French nationwide study enrolling 41 patients. Medicine. 2016;95:e3548.","journal-title":"Medicine"},{"key":"1213_CR12","doi-asserted-by":"crossref","unstructured":"Willrich MA Braun KM, Moyer AM, Jeffrey DH, Frazer-Abel A 2021 Complement testing in the clinical laboratory. Crit Rev Lab Sci 1\u201351.","DOI":"10.1080\/10408363.2021.1907297"},{"key":"1213_CR13","first-page":"38","volume":"13","author":"Public Health England","year":"2019","unstructured":"Public Health England. Invasive meningococcal disease in England: annual laboratory confirmed reports for epidemiological year 2018 to 2019. Health Prot Rep. 2019;13:38.","journal-title":"Health Protection Report"},{"key":"1213_CR14","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1136\/adc.86.3.215","volume":"86","author":"S Hoare","year":"2002","unstructured":"Hoare S, El-Shazali O, Clark JE, Fay A, Cant AJ. Investigation for complement deficiency following meningococcal disease. Arch Dis Child. 2002;86:215\u20137.","journal-title":"Arch Dis Child"},{"key":"1213_CR15","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1016\/j.molimm.2010.05.007","volume":"47","author":"VP Ferreira","year":"2010","unstructured":"Ferreira VP, Pangburn MK, Cort\u00e9s C. Complement control protein factor H: the good, the bad, and the inadequate. Mol Immunol. 2010;47:2187\u201397.","journal-title":"Mol Immunol"},{"key":"1213_CR16","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/1750-1172-7-42","volume":"7","author":"M Alba-Dom\u00ednguez","year":"2012","unstructured":"Alba-Dom\u00ednguez M, L\u00f3pez-Lera A, Garrido S, Nozal P, Gonz\u00e1lez-Granado I, Melero J, et al. Complement factor I deficiency: a not so rare immune defect Characterization of new mutations and the first large gene deletion. Orphanet J Rare Dis. 2012;7:42.","journal-title":"Orphanet J Rare Dis"},{"key":"1213_CR17","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00281-017-0663-8","volume":"40","author":"EK Wong","year":"2018","unstructured":"Wong EK, Kavanagh D. Diseases of complement dysregulation\u2013an overview. Semin Immunopathol. 2018;40:49\u201364.","journal-title":"Semin Immunopathol"},{"key":"1213_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr6909a1","volume":"69","author":"SA Mbaeyi","year":"2020","unstructured":"Mbaeyi SA, Bozio CH, Duffy J, Rubin LG, Hariri S, Stephens DS, et al. Meningococcal vaccination: recommendations of the advisory committee on immunization practices, United States, 2020. MMWR Recomm Rep. 2020;69:1\u201341.","journal-title":"MMWR Recomm Rep"},{"key":"1213_CR19","doi-asserted-by":"publisher","first-page":"3389","DOI":"10.3389\/fimmu.2019.01272","volume":"10","author":"SM El-Helou","year":"2019","unstructured":"El-Helou SM, Biegner AK, Ehl SR, Heeg M, Maccari ME, Ritterbusch H, et al. The German national registry of primary immunodeficiencies (2012\u20132017). Front Immunol. 2019;10:3389.","journal-title":"Front Immunol"},{"key":"1213_CR20","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/S0022-3476(89)80793-0","volume":"114","author":"M Nagata","year":"1989","unstructured":"Nagata M, Hara T, Aokl T, Mizuno Y, Akeda H, Inaba S, et al. Inherited deficiency of ninth component of complement: an increased risk of meningococcal meningitis. J Pediatr. 1989;114:260\u20134.","journal-title":"J Pediatr"},{"key":"1213_CR21","first-page":"1","volume":"15","author":"Public Health England","year":"2021","unstructured":"Public Health England. Invasive meningococcal disease in England: annual laboratory confirmed reports for epidemiological year 2019 to 2020. Health Prot Rep. 2021;15:1\u20138.","journal-title":"Health Protection Report"},{"key":"1213_CR22","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1097\/00005792-199311000-00002","volume":"93","author":"AE Platonov","year":"1993","unstructured":"Platonov AE, Beloborodov VB, Vershinina IV. Meningococcal disease in patients with later complement component deficiency: studies in the U.S.S.R. Medicine. 1993;93:374\u201392.","journal-title":"Medicine"},{"key":"1213_CR23","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1128\/CMR.00048-09","volume":"23","author":"S Ram","year":"2010","unstructured":"Ram S, Lewis LA, Rice PA. Infections of people with complement deficiencies and patients who have undergone splenectomy. Clin Microbiol Rev. 2010;23:740\u201380.","journal-title":"Clin Microbiol Rev"},{"key":"1213_CR24","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1007\/s10875-020-00754-1","volume":"40","author":"N Brodszki","year":"2020","unstructured":"Brodszki N, Frazer-Abel A, Grumach AS, Kirschfink M, Litzman J, Perez E, et al. European society for immunodeficiencies (ESID) and European reference network on rare primary immunodeficiency, autoinflammatory and autoimmune diseases (ERN RITA) complement guideline: deficiencies, diagnosis, and management. J Clin Immunol. 2020;40:576\u201391.","journal-title":"J Clin Immunol"}],"container-title":["Journal of Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-022-01213-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10875-022-01213-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-022-01213-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T04:24:26Z","timestamp":1650428666000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10875-022-01213-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,27]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["1213"],"URL":"https:\/\/doi.org\/10.1007\/s10875-022-01213-9","relation":{},"ISSN":["0271-9142","1573-2592"],"issn-type":[{"type":"print","value":"0271-9142"},{"type":"electronic","value":"1573-2592"}],"subject":[],"published":{"date-parts":[[2022,1,27]]},"assertion":[{"value":"20 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval was obtained from the National UK Ethics Committee (IRAS number 259418).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Written consent was obtained from patients or their parents.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Ethics approval and written consent included consent for publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}